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Abstract 
Introduction: Glutamate dysfunction has been implicated in the pathophysiology of 
schizophrenia. The metabotropic glutamate receptors (mGluRs) are G-protein-coupled 
receptors. GRM7, the gene that encodes mGluR7, is expressed in many regions of the human 
central nervous system. The GRM7 gene is located on human chromosome 3p26, which has 
been suggested by linkage analysis to contain a susceptibility locus for schizophrenia. 
Methods: We screened for mutations in all exons, exon/intron junctions, and promoter 
regions of the GRM7 gene in Japanese patients with schizophrenia and evaluated associations 
between the detected polymorphisms and schizophrenia. We examined the influence of one 
polymorphism associated with schizophrenia on the expression of GRM7 by dual luciferase 
assay in transfected cells.  
Results: Twenty-five polymorphisms/mutations were detected in GRM7. Case-control 
analysis revealed a potential association of a synonymous polymorphism (371T/C, 
rs3749380) in exon 1 with schizophrenia in our case-control study of 2293 Japanese patients 
with schizophrenia and 2382 Japanese control subjects (allelic p = 0.009). Dual luciferase 
assay revealed suppression of transcription activity by exon 1 containing this polymorphism 
and a statistically significant difference in the promoter activity between the T and C alleles.  
Conclusions: Our results support the possible association of a GRM7 gene polymorphism 
with genetic susceptibility to schizophrenia. 
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Introduction 
Schizophrenia is a severe psychiatric disorder, which is equally prevalent in men and 
women and affects approximately one percent of the population worldwide. Several 
neurotransmitter systems and functional networks within the brain have been found to be 
affected in patients with schizophrenia. The glutamatergic neuronal dysfunction hypothesis is 
one of the main explanatory hypotheses (Carlsson et al., 1997). Glutamate is the primary 
excitatory neurotransmitter in brain. It is contained as a neurotransmitter in approximately 
60% of brain neurons, including almost all cortical pyramidal neurons. Further, virtually 
100% of brain neurons contain some type of glutamate receptor. Glutamate mediates its 
effects on the central nervous system via both ionotropic and metabotropic receptors. The 
metabotropic glutamate receptors (mGluRs), which are G protein-coupled receptors, are 
divided into 3 groups on the basis of sequence homology, putative signal transduction 
mechanisms, and pharmacologic properties (Nakanishi 1994; Pin and Duvoisin 1995). The 
mGluRs in group I are mGluR1 and mGluR5, those in group II are mGluR2 and mGluR3, and 
those in group III are mGluRs 4, 6, 7, and 8. Group II and group III mGluRs are linked to 
inhibition of the cyclic AMP cascade but differ in their agonist selectivities.    
mGluR7 is the most highly conserved mGluR subtype across mammalian species 
(Flor et al., 1997). Makoff et al (1996) observed by in situ hybridization that GRM7 is 
expressed in many areas of the human brain, especially the cerebral cortex, hippocampus, and 
cerebellum. mGluR7 is localized directly in the presynaptic zone of the synaptic cleft of 
glutamatergic synapses (Kinoshita et al 1998; Kosinski et al 1999), where it is thought to act 
as an autoreceptor that is activated by glutamate released from the presynaptic terminal during 
action potentials. Furthermore, mGluR7 is thought to be a key player in shaping synaptic 
responses at glutamatergic synapses as well as in regulating key aspects of inhibitory 
GABAergic transmission (Kinoshita et al 1998; Kosinski et al 1999).  
mGluR7 has putative roles in anxiety, emotional responses, and spatial working 
memory (Callaerts-Vegh et al 2006; Cryan et al 2003; Mitsukawa et al 2006). Cognitive 
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dysfunction is estimated to occur in 75%–85% of patients with schizophrenia, often precedes 
the onset of other symptoms (Reichenberg et al 2006). Working memory is one of primary 
cognitive domains that are crucial for developing targets for the treatment of cognition in 
schizophrenia (Nuechterlein et al 2004). 
mGluR7 ablation causes dysregulation of the hypothalamic-pituitary-adrenal axis and 
increases hippocampal BDNF protein levels (Mitsukawa et al 2005). Dysregulation of BDNF 
production or release is associated with neuropsychiatric disorders, such as schizophrenia 
(Kelley 2004; Harrison and Weinberger 2005). Association between the val66met 
polymorphism of the BDNF gene and hippocampal volume in human, particularly in patients 
with schizophrenia (Szeszko PR et al 2005).  
In the present study, we examined the GRM7 gene as a candidate for schizophrenia.  
 
Materials and Methods 
Subjects 
All subjects were of Japanese descent and were recruited from the main island of 
Japan. Patients with schizophrenia were diagnosed according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV). Control subjects were mentally 
healthy, unrelated subjects with no self-reported family history of mental illness within 
second-degree relatives. We sequenced the 5’ region, exons and exon-intron boundaries of the 
GRM7 gene in 32 patients (mutation screening patients) with schizophrenia (mean age ± SD, 
46.5 ± 10.9 years; 17 men and 15 women) to identify polymorphisms. We then genotyped 576 
patients including the mutation screening patients (mean age ± SD, 46.6 ± 14.8 years; 322 
men and 254 women) and 576 control subjects (mean age ± SD, 46.8 ± 12.9 years; 268 men 
and 308 women) (1st association population) with Predesigned TaqMan single nucleotide 
polymorphism (SNP) genotyping assays. When Predesigned TaqMan SNP genotyping assays 
were not available, we performed direct sequencing of DNAs from 96 patients including the 
mutation screening patients (mean age ± SD, 50.3 ± 13.1 years; 55 men and 40 women) and 
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96 control subjects (mean age ± SD, 53.6 ± 9.1 years; 42 men and 54 women). For SNPs for 
which an association with schizophrenia was suggested in the first association population, we 
performed genotyping in an independent sample of 1817 patients (mean age ± SD, 45.5 ± 
14.1 years; 962 men and 855 women) and 1728 control subjects (mean age ± SD, 46.2 ± 13.6 
years; 958 men and 770 women) (confirmation population). The present study was approved 
by the ethics committees of the University of Tsukuba and participating institutes. All 
participants provided written informed consent. 
 
DNA isolation and genotyping 
DNAs were extracted from peripheral lymphocytes by standard phenol-chloroform 
extraction. The genomic structure of GRM7 was determined from the University of California 
at Santa Cruz (UCSC) database (http://genome.ucsc.edu/cgi-bin/hgGateway) and the National 
Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/). To 
screen for polymorphisms, we performed direct sequencing of genomic DNAs with a Big Dye 
Terminator Cycle Sequencing Kit and the ABI PRISM 3100 Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA). All exons, exon-intron junctions, and 1.6 kb of the 5’ 
flanking region of GRM7 were amplified from the genomic DNAs of 24 randomly selected 
patients. The sequences of primers and conditions used for amplification for the mutation 
screening are available upon request. We genotyped polymorphisms with the TaqMan SNP 
Genotyping Assay (Applied Biosystems) and ABI PRISM 7900HT Sequence Detection 
System (Applied Biosystems). 
 
Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was isolated from cultured cells with the SV Total RNA Isolation System 
(Promega, Madison, WI, USA). cDNA was synthesized from RNA with Revertra Ace 
(Toyobo, Tokyo, Japan) and oligo dT primer. Expression of GRM7 was quantified by 
real-time quantitative RT-PCR with the TaqMan Gene Expression Assay and ABI PRISM 
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7900HT Sequence Detection System (Applied Biosystems) per the manufacturer’s 
instructions. Primers and probes were purchased from Applied Biosystems 
(Assays-on-Demand Assay ID: Hs00179051_m1). GAPDH was used as an internal control. 
Data were collected and analyzed with Sequence Detector Software (SDS) version 2.1 
(Applied Biosystems) and the standard curve method.  
 
Luciferase reporter assay 
To assay promoter activity of the 5’-flanking region and exon 1 of the GRM7 gene, 9 
fragments of the 5’ region were cloned into the pGL3-Basic plasmid with and without a 
Simian virus 40 enhancer sequence (Promega, Madison, WI, USA). The day before 
transfection, NH-12 cells (Japanese Collection of Research Bioresources Gene Bank, 
http://genebank.nibio.go.jp/gbank/index_e.html) were plated at 1 X 105 cells per well in a 
24-well plate and grown in DMEM (Sigma, St. Louis, MO, USA) supplemented with 10% 
fetal bovine serum (FBS) (Equitech-Bio, Kerrville, TX, USA). One microgram of each test 
plasmid was transiently cotransfected into the cells with 0.1 μg of pRL-TK plasmid (an 
internal standard reporter) (Promega) with Lipofectamine 2000 (Invitrogen) per 
manufacturer's protocol. After 48 h, the dual-luciferase assay was performed with a PicaGene 
Dual SeaPansy Kit (Toyo Ink, Tokyo, Japan) according to the manufacturer’s instructions. 
 
Statistics 
 Deviation from predicted Hardy-Weinberg frequencies was examined by chi-square 
test. Individual allelic associations were examined by Fisher’s exact test. Genotypic 
associations were examined by Armitage’s Trend Test for the reasons discussed by Devlin and 
Roeder (Devlin and Roeder 1999). A significant association was defined when the given p 
value for allelic or genotypic tests was less than 5% (uncorrected p < 0.05) and the same 
association was confirmed in an independent population with p < 0.05. Linkage 
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disequilibrium (LD) between polymorphisms and haplotype block structures was evaluated 
with Haploview software version 3.11 (Barrett et al 2005). Haplotype blocks were generated 
with the default algorithm taken from Gabriel et al (Gabriel et al 2002). Haplotypic 
associations with disorders were examined with Haploview software, which performs 
association tests on the set of blocks selected by obtaining counts for case control association 
tests by summing the fractional likelihoods of each individual for each haplotype by the EM 
algorithm.  
 
Results 
Twenty-five polymorphisms/mutations were detected in the exons, exon-intron 
junctions, and 5’-flanking region of the GRM7 gene (Figure 1). Genotyping was carried out 
for all detected polymorphisms except rare variants with allele frequencies < 0.05 and 
polymorphisms in LD with each other (r2 = 1). Among these SNPs, 1724A/G (rs34373930), 
1938C/T (rs7614915), IVS8+49T/A (T/A at the position of 49 base-pair starting from the G of 
the donor site of intron 8), and 2345C/T (rs1485175) were in complete LD (r2 = 1), and 
IVS8+114T/C and 2384G/A (rs1485174) were also in complete LD (r2 = 1) in 24 screening 
samples. Therefore, we genotyped the 2345C/T and 2384G/A polymorphisms as 
representative SNPs. The IVS9+97C/T, 2912T/C, and 3292(A)3-4 (rs3840229) SNPs were 
genotyped in 96 patients and 96 controls by direct sequencing, and the other 12 SNPs were 
genotyped in 576 patients and 575 control subjects by TaqMan SNP Genotyping Assay 
(Applied Biosystems). The genotypic distributions of these 15 SNPs did not deviate 
significantly from Hardy-Weinberg equilibrium (p > 0.05). A synonymous polymorphism 
(371T/C) in exon 1 of GRM7 showed a potential association for schizophrenia (allelic 
uncorrected p = 0.04) (Table 1). We did not detect a significant association with schizophrenia 
of any of the other 14 SNPs, including the Tyr433Phe polymorphism (allelic uncorrected p = 
0.33; genotypic uncorrected p = 0.63), which was previously reported to be associated 
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(Bolonna et al 2001). The haplotype blocks consisted of IVS1-76T/C, IVS1-67A/G, and 
IVS1-23G/A and of 2345C/T and 2384A/G. No significant haplotypic association was 
suggested for these 2 haplotype blocks (p > 0.05). We confirmed the association of the 
371T/C polymorphism with schizophrenia in an independent population of 1717 patients and 
1807 control subjects and confirmed the association (allelic p = 0.03, one-sided) (Table 2). 
The allelic p value of the association in the total population of 2293 patients with 
schizophrenia and 2382 control subjects was 0.009 (Table 2). According to the HapMap 
database (http://www.hapmap.org/index.html), the 371T/C polymorphism (rs3749380) was 
not in the LD block and was not in LD with other SNPs within 80 kb (r2 < 0.7). Weak LD was 
observed with rs458351 (D’ = 0.89 and r2 = 0.69), which is 30 kb upstream of rs3749380.  
Expression of GRM7 mRNA was assessed by RT-PCR in 7 different human cell lines 
(IMR-32, NH-12, TN-2, NB-1, SCCH-26, A172, and T98G). GRM7 was expressed in NH-12 
and SCCH-26 cells (data not shown). Because expression in NH-12 cells was higher than in 
SCCH-26 cells, we used NH-12 cells, a human cell line derived from neuroblastoma, for 
luciferase assays. Dual luciferase assay revealed that the strongest promoter activity for 
GRM7 was contained in the 1-kb fragment upstream of the ATG site of exon 1. However, a 
promoter construct containing the sequence from the ATG to the end of exon 1 showed 
significantly lower activity, indicating that the 371T/C polymorphism is in a regulatory region. 
When an SV40 enhancer was added downstream of the luciferase gene, the 371C allele 
showed significantly higher promoter activity than the 371T allele (Figure 2).  
 
Discussion 
In the present study, we examined associations between polymorphisms in the GRM7 
gene and schizophrenia. Weak association was found for a synonymous SNP (371T/C) in 
exon 1 in the first association population, and this association was replicated in the 
confirmation population. The T allele, which is associated with schizophrenia, has lower 
promoter activity than the C allele. On the basis of this finding, we hypothesized that lower 
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expression of mGluR7 may increase risk of developing schizophrenia, though studies of the 
expression of GRM7 in brains of patients with schizophrenia have not been reported. 
mGluR7 was the first group III mGluR found to be enriched presynaptically at active 
zones of hippocampal pyramidal cells (Shigemoto et al 1996). The low affinity of mGluR7 for 
glutamate suggests that mGluR7 might act as a “low-pass filter” that suppresses release of 
glutamate only when action potentials arriving at a high frequency produce massive glutamate 
release. The interaction with PICK1 (protein interacting with PRKCA 1) is crucial for the 
clustering of mGluR7 at presynaptic release sites (Boudin et al 2000). PICK1 is reported to be 
associated with schizophrenia (Dev and Henley 2006; Fujii et al 2006). 
In the present study, we found an association between a functional SNP, 371T/C, in 
the gene encoding mGluR7 and schizophrenia. Recently, a genome-wide association study of 
2000 individuals with bipolar disorder and 3000 control subjects found a strong association of 
SNP marker rs1485171 (p = 9.7 X 10-5) in GRM7 with bipolar disorder (Consortium 2007; 
Consortium. 2007). Therefore, genetic variations in the GRM7 gene may be involved in both 
schizophrenia and bipolar disorder.  
An association between Tyr433Phe polymorphism of GRM7 and schizophrenia was 
reported (Bolonna et al 2001). However, we failed to detect the association (allele, p = 0.33; 
genotype, p = 0.63). Recently, a copy number variation of the GRM7 locus has been reported 
in patients with schizophrenia (Wilson et al 2006). In the present study, we did not observe 
significant deviation from Hardy-Weinberg expectancy of the genotypic distributions of SNPs, 
indicating that copy number variations at the SNP examined in the present study are not 
common and are unlikely.  
In the present study, the association of 371T/C with schizophrenia was observed in 
two independent case control populations. However, its weak association (OR = 1.12) 
requires replication studies in large sample populations of more than 2000 cases and 2000 
control subjects with a power greater than 0.8. We believe that GRM7 is an interesting target 
worth such studies for schizophrenia and other psychiatric disorders. 
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FIGURE LEGENDS 
Figure 1. Schematic representation of the GRM7 gene and relevant mutations/polymorphisms 
(A), linkage disequilibrium plot of the Japanese population from HapMap database (B), and 
between SNPs genotyped in this study shown in Table 1 (C). Figures in rhombus are D’ 
between SNPs and filled rhombus without figures indicates D’ = 1 in (C). 
 
Figure 2. Luciferase assays. 
(A) Schematic representation of the GRM7 gene and reporter gene constructs.  
(B) Transcriptional activity of various constructs of the 5’ region and exon 1 of the human 
GRM7 gene in NH-12 cells. The region indicated by fine lines were not included in the 
constructs. Cotransfections were performed with pRL-TK (Renilla luciferase) to 
normalize transfection efficiency. Luciferase activity was assayed 48 h after transfection. 
Relative ratio of expression is shown as relative to that of pGL3-Basic, which was set at 1. 
The mean ±SEM was calculated from triplicate assays. 
(C) Effect of the 371C/T polymorphism on GRM7 promoter activity. This assay was 
performed with pGL3-enhancer vector, because the constructs that contain GRM7 exon 1 
show extremely low luciferase activity. 
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 Table 1. Genotypic and allelic distributions of polymorphisms in the GRM7 gene     
Polymorphism Population n Genotype count (frequency) p Allele count (frequency) p 
371T/C (rs3749380)  CC TC TT  C T  
 Patients 576 241 (0.42) 256 (0.44) 79 (0.14)  738 (0.64) 414 (0.36)  
 Controls 575 274 (0.48) 236 (0.41) 65 (0.11) 0.04 784 (0.68) 366 (0.32) 0.04 
IVS1-76T/C (rs3749450) CC TC TT  C T  
 Patients 568 10 (0.02) 148 (0.26) 410 (0.72)  168 (0.15) 968 (0.85)  
 Controls 561 18 (0.03) 129 (0.23) 414 (0.74) 0.95 165 (0.15) 957 (0.85) 0.96 
IVS1-67A/G (rs3749449) GG AG AA  G A  
 Patients 570 8 (0.01) 95 (0.17) 467 (0.82)  111 (0.10) 1029 (0.90)  
 Controls 567 7 (0.01) 89 (0.16) 471 (0.83) 0.60 103 (0.09) 1031 (0.91) 0.59 
IVS1-23G/A (rs3749448) AA GA GG  A G  
 Patients 569 26 (0.05) 181 (0.32) 362 (0.64)  233 (0.20) 905 (0.80)  
 Controls 566 30 (0.05) 178 (0.31) 358 (0.63) 0.75 238 (0.21) 894 (0.79) 0.75 
IVS4-35C/T (rs712774) CC CT TT  C T  
 Patients 571 121 (0.21) 260 (0.46) 190 (0.33)  502 (0.44) 640 (0.56)  
 Controls 559 117 (0.21) 268 (0.48) 174 (0.31) 0.66 502 (0.45) 616 (0.55) 0.65 
1447T/A (rs2229902, Phe433Tyr) AA AT TT  A T  
 Patients 575 488 (0.85) 81 (0.14) 6 (0.01)  1057 (0.92) 93 (0.08)  
 Controls 569 484 (0.85) 82 (0.14) 3 (0.01) 0.76 1050 (0.92) 88 (0.08) 0.75 
2345C/T (rs1485175)  CC CT TT  C T  
 Patients 569 120 (0.21) 275 (0.48) 174 (0.31)  515 (0.45) 623 (0.55)  
 Controls 562 118 (0.21) 282 (0.50) 162 (0.29) 0.69 518 (0.46) 606 (0.54) 0.69 
2384A/G (rs1485174)  AA GA GG  A G  
 Patients 569 18 (0.03) 150 (0.26) 401 (0.70)  186 (0.16) 952 (0.84)  
 Controls 561 24 (0.04) 162 (0.29) 375 (0.67) 0.15 210 (0.19) 912 (0.81) 0.14 
IVS8-123T/C (rs162802) CC TC TT  C T  
 Patients 569 3 (0.01) 91 (0.16) 475 (0.83)  97 (0.09) 1041 (0.91)  
 Controls 566 9 (0.02) 88 (0.16) 469 (0.83) 0.49 106 (0.09) 1026 (0.91) 0.48 
IVS9+15G/A (rs2280739) AA GA GG  A G  
 Patients 570 4 (0.01) 84 (0.15) 482 (0.85)  92 (0.08) 1048 (0.92)  
 Controls 564 3 (0.01) 86 (0.15) 475 (0.84) 0.94 92 (0.08) 1036 (0.92) 0.94 
IVS9e+97C/T  CC CT TT  C T  
 Patients 96 75 (0.78) 20 (0.21) 1 (0.01)  170 (0.89) 22 (0.11)  
 Controls 95 78 (0.82) 16 (0.17) 1 (0.01) 0.53 172 (0.91) 18 (0.09) 0.62 
IVS9e+131C/T (rs162777) CC CT TT  C T  
 Patients 570 22 (0.04) 186 (0.33) 362 (0.64)  230 (0.20) 910 (0.80)  
 Controls 566 23 (0.04) 178 (0.31) 365 (0.64) 0.82 224 (0.20) 908 (0.80) 0.82 
2912T/C  TT TC CC  T C  
 Patients 96 78 (0.81) 18 (0.19) 0 (0.00)  174 (0.91) 18 (0.09)  
 Controls 95 83 (0.87) 12 (0.13) 0 (0.00) 0.32 178 (0.94) 12 (0.06) 0.34 
3175C/T (rs9826579)  CC CT TT  C T  
 Patients 574 25 (0.04) 203 (0.35) 346 (0.60)  253 (0.22) 895 (0.78)  
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 Controls 567 23 (0.04) 189 (0.33) 355 (0.63) 0.44 235 (0.21) 899 (0.79) 0.44 
3292(A)3-4 (rs3840229) 33 34 44  3 4  
 Patients 96 80 (0.83) 16 (0.17) 0 (0.00)  176 (0.92) 16 (0.08)  
 Controls 95 78 (0.82) 17 (0.18) 0 (0.00) 0.85 173 (0.91) 17 (0.09) 0.86 
Genotypic p was calculated by Armitage’s Trend Test and allelic p was calculated by Fisher's exact test.  
 
Table 2. Association of the 371T/C polymorphism (rs3749380) in the GRM7 gene with schizophrenia     
Polymorphism Genotype count (frequency)  Allele count (frequency)  
population n CC CT TT p C T p 
Screening population             
Patients 576 241 (0.42) 256 (0.44) 79 (0.14)  738 (0.64) 414 (0.36)  
Controls 575 274 (0.48) 236 (0.41) 65 (0.11) 0.04  784 (0.68) 366 (0.32) 0.04 
Confirmatory population CC CT TT  C T  
Patients 1717 715 (0.42) 771 (0.45) 231 (0.13)  2201 (0.64) 1233 (0.36)  
Controls 1807 799 (0.44) 794 (0.44) 214 (0.12) 0.07 2392 (0.66) 1222 (0.34) 0.03 
Total  CC CT TT  C T  
Patients 2293 956 (0.42) 1027 (0.45) 310 (0.14)  2939 (0.64) 1647 (0.36)  
Controls 2382 1073 (0.45) 1030 (0.43) 279 (0.12) 0.01  3176 (0.67) 1588 (0.33) 0.009* 
Genotypic p was calculated by Armitage’s Trend Test and allelic p was calculated by Fisher's exact test.     
*Odd ratio = 1.12, 95% confidence interval = 1.03-1.22      
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